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Abstract: Three-dimensional (3D) printing is a recent technology, which gives the possibility to 
manufacture personalised dosage forms and it has a broad range of applications. One of the most 
developed, it is the manufacture of oral solid dosage and the four 3DP techniques which have been 
more used for their manufacture are FDM, inkjet 3DP, SLA and SLS. This systematic review is car-
ried out to statistically analyze the current 3DP techniques employed in manufacturing oral solid 
formulations and assess the recent trends of this new technology. The work has been organised into 
four steps, (1) screening of the articles, definition of the inclusion and exclusion criteria and classifi-
cation of the articles in the two main groups (included/excluded); (2) quantification and characteri-
sation of the included articles; (3) evaluation of the validity of data and data extraction process; (4) 
data analysis, discussion, and conclusion to define which technique offers the best properties to be 
applied in the manufacture of oral solid formulations. It has been observed that with SLS 3DP tech-
nique, all the characterisation tests required by the BP (drug content, drug dissolution profile, hard-
ness, friability, disintegration time and uniformity of weight) have been performed in the majority 
of articles, except for the friability test. However, it is not possible to define which of the four 3DP 
techniques is the most suitable for the manufacture of oral solid formulations, because the selection 
is affected by different parameters, such as the type of formulation, the physical-mechanical prop-
erties to achieve. Moreover, each technique has its specific advantages and disadvantages, such as 
for FDM the biggest challenge is the degradation of the drug, due to high printing temperature 
process or for SLA is the toxicity of the carcinogenic risk of the photopolymerising material. 
Keywords: 3D printing; oral solid dosage forms; tablets; systematic review 
 
1. Introduction 
Three-dimensional printing, also referred to as additive layer manufacturing, is a 
revolutionary, user-friendly and versatile technique that allows 3D designs to be con-
verted into real structures. This method of manufacturing can be applied in drug delivery 
to fabricate 3DP drug delivery systems with precise and complex geometries through se-
quential layering [1-5]. 3D objects are designed using the CAD software, which converts 
the 3D model into an STL file that contains information related to the surface geometry of 
the 3D object. Subsequently, the STL file is sliced into layers, producing a slice file (SLI) 
that is then loaded into a machine (3D printer) which guides the motions of the build parts 
[6]. During printing, the raw material is first extruded across the x-y axis and then along 
the z-axis, to achieve the desired dimensions [7–10]. 
The substitution of conventional techniques with 3DP gave the possibility to provide 
personalised polypills to the patients, fabricated to decrease the costs of production and 
to improve the adherence to the therapy. Moreover, the first time that 3DP was used in 
the pharmaceutical area, was 1996 when a PB was employed to fabricate a 3D solid struc-
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ture with a drug [10]. Subsequently, other 3D printing techniques were introduced. In-
deed, in the late 1980s, was developed SLS by Carl Deckard and instead, in 1990, FDM by 
Sachs et al. [11,12]. 
3DP has a broad range of applications in different fields such as fabrication of proto-
types, part consolidation, maintenance and repair in aviation and automobile industries 
as well as printing of human organs, prosthetics and implants in the biomedical industry. 
In pharmaceutical manufacturing, 3D printing can be used to accurately spread materials, 
allowing an easier fabrication of medications with individualised and personalised doses 
and polypills which contain more than one API. Moreover, 3DP allows the production of 
highly precise formulations, characterised by several geometries and dimensions, allow-
ing the local drug delivery to specific organs, and offering versatile drug release rates [7]. 
Furthermore, 3DP technique has been used to manufacture orodispersible tablets, 
medical devices, doughnut-shaped tablet, polypills, channelled tablets, printed loaded 
with nanocapsules and duo caplets [13–16]. 
One of the principal applications of 3DP is the manufacturing of oral solid drug de-
livery systems, including a variety of complex geometries with different types of drug 
release profiles, such as immediate and modified as well as formulations with multiple 
APIs to enhance the personalisation. This is especially beneficial to patients with phar-
macogenetic polymorphism or treated with drugs characterised by a narrow therapeutic 
index [17]. 
SPRITAM® (levetiracetam) is the first 3DP rapidly disintegrating oral formulation, 
approved by FDA in 2015, produced by Aprecia Pharmaceutics. It was realised through 
the ZipDose technology, which is a powder bed inkjet system, that allows the production 
of formulations with different values of strength, showing the potential benefit of 3DP 
technique to produce personalised medicines answering to the specific needs of each pa-
tient. This orodispersible tablet presents a quick mouth dispersion (~11 s) and is easy to 
swallow [11,17]. 
3DP techniques, are based on a number of techniques to building 3D parts point-by-
point, line-by-line, or layer-by-layer. Based on the manufacturing principle, the main em-
ployed 3DP techniques in the pharmaceutical area can be classified into four categories: 
(a) FDM; (b) SLS; (c) SLA; and inkjet 3DP. These techniques generally undergo the follow-
ing steps for manufacturing; first, the 3D model is designed using the CAD software, ma-
terials are then prepared during which the defined drugs and polymers are mixed and 
transferred into the 3D printer. As the last step, the mix of drug and polymer is consoli-
dated or ejected through a printer system to allow the fabrication of the 3D drug delivery 
system layer-by-layer [4]. Figure 1 shows a schematic diagram of FDM, SLS, SLA, and 
inkjet printing. 





Figure 1. Schematic diagram of (a) FDM; (b) SLS; (c) SLA; (d) and inkjet 3DP. 
Inkjet 3DP printing was the first technique used to print 3D systems in the pharma-
ceutical area, where a liquid material is specifically and selectively jetted onto a substrate. 
The printing process is organised into three different stages, (1) droplets generation; (2) 
deposition of the ink droplets and interaction with a substrate; (3) solidification step. 
Inkjet 3DP process is known also as drop-on-powder (DoP) and it allows the formation of 
both a thin layer and a powder layer, where a binder liquid is deposited in a precise way. 
Once this binder leads to the solidification of the layer, a new powder layer is produced 
on the top and all the previous steps are repeated until the final formulation is manufac-
tured [18]. 
Inkjet printing technology could involve a continuous jetting of droplets, where a 
catcher is used to collect the unwanted jetted droplets, or as with a drop-on-demand 
(DOD), a system where ink droplets are ejected when required. The DOD system is further 
classified based on the mechanism of droplets formation. The thermal inkjet mechanism 
involves the use of a thermal resistor that is rapidly heated to allow the vaporisation of 
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out of the nozzle. In piezoelectric inkjet mechanism, on the other hand, a piezoelectric 
material is used and once a voltage is applied to this material, this leads to the mechanical 
deformation, which causes the ejection of the ink droplets. Furthermore, this second 
mechanism is considered more advantageous than the first due to the low risk of thermal 
degradation of heat-sensitive ink in response to the heat [19–21]. 
The main advantages of the inkjet 3DP include a reduced number of steps to manu-
facture personalised tablets and control of the drug release by varying specific printing 
parameters such as size or surface area of the printed geometry, loading of jetted droplets, 
changing the droplet spacing on the substrate and also the freedom of spatial location of 
a drug delivery system. Furthermore, other positive aspects of this 3DP systems are the 
achievement of a high degree of uniformity, reproducibility, and accuracy for high-reso-
lution applications. Moreover, inkjet printing is characterised by low costs and the possi-
bility to deposit simultaneously, multiple materials and the amount of material released 
is affected by the size of the printer and by the number of jets [20]. 
The main challenge of the DoP process is the development of the ink itself because 
its physiochemical properties could strongly affect the printability. Moreover, it is rele-
vant to develop reliable printable ink, which can also maintain its product functionality 
[18,19]. 
FDM an extrusion-based technique is the second 3DP technology analysed and is 
based on the deposition of different layers of molten material, which are delivered to the 
printer in the form of the thermoplastic polymer filaments. The polymers used for this 
type of 3DP system are carefully selected based on their physical properties as ther-
moresponsive polymers with notable biocompatibility suitable for biomedical applica-
tions. Examples include polymers such as PCL and PLGA [11]. 
During FDM printing, the thermoplastic material which is made available in the form 
of filaments is passed through a heated nozzle where the polymer undergoes a melting 
process to be extruded at a specific predefined rate and pressure. The melted polymer in 
a semi-liquid state is deposited layer by layer onto a building platform to allow them to 
harden [10]. The nozzle head can be moved in three different directions, leading to the 
deposition of a thin layer onto the platform. During the extrusion process, the material 
undergoes a reduction of its temperature and solidify, forming the 3D model layer-by-
layer. The FDM can also present more than one print head, and each of them is controlled 
independently, and it allows the extrusion of several materials, whose deposition depends 
on the CAD model and on the printer parameters [11]. 
This technology has been used in the pharmaceutical field and allows the manufac-
turing of 3DP drug delivery systems, and both the melting temperature and the tempera-
ture of the nozzle depends on the type of polymer to be extruded [11]. It is possible to 
incorporate drugs into filaments using methods such as impregnation and HME. The 
HME process, which is the more popular method, involves using a hot melt extruder to 
facilitate melting, mixing and extrusion of drug, polymer and excipient. A successfully 
formulated and extruded mixture would emerge in the form of a drug-loaded filament. 
On one hand, the main advantages of this technique include having a higher resolu-
tion compared to some of the other 3DP technologies, good mechanical strength and de-
sign flexibility that allows easy modification of some printing parameters, such as the infill 
percentage of printlets to obtain a desired drug release profiles of the printed dosage 
forms. On the other hand, the main limitation is the possible risk of drug degradation that 
may result from the use of a significant amount of heat. Indeed, in many cases, a temper-
ature higher than 120 °C is used, which can lead to drug degradation, deterioration of 
mechanical properties, decrease of the physical stability, filaments ageing and relatively 
poor resolution of the 3DP objects. Moreover, the bioactivity of the drugs can be altered 
due to the melting temperature of the polymers to be extruded and to avoid this, it is 
relevant to select an appropriate drug, whose melting point is above one of the polymers 
[12]. By appropriately selecting the process parameters and material composition of the 




filament, it is possible to manufacture high-quality filaments containing the API (active 
pharmaceutical ingredient) [10,22]. Other drawbacks include a reduced choice of thermo-
plastic materials with good melting-viscosity properties for the extrusion process and the 
difficulty of loading thermo-sensitive drugs during the extrusion process caused by the 
high processing temperatures [5,11]. 
The third 3DP technique considered was SLA which is a simple and fast technology 
that has been used to create 3D objects and drug-loaded formulations through the solidi-
fication of a photoreactive liquid resin which is achieved by photopolymerisation. SLA is 
the first technique that produced reduced drug degradation, a property that can be con-
sidered useful for the printing of tablets with thermo-sensitive drugs [5]. SLA process uses 
a focused ultraviolet (UV) light or laser to selectively polymerise several layers of photo-
sensitive and photocurable polymer materials contained inside a resin tank. Solid 3D for-
mulations are created by the occurrence of this photopolymerisation reaction during 
which a liquid monomer is converted into a solid polymer. Additionally, a photoinitiator 
(a light-sensitive compound), which becomes active with suitable wavelengths, is added 
to allow the beginning of the reaction and the formation of free radicals, which will then 
be used to convert the liquid monomer into a solid-state [20]. Once the photoinitiator is 
activated at a specific wavelength, it absorbs energy to produce free radicals and begin 
the reaction [5,20]. SLA has the ability not only to produce large parts, but also high reso-
lution and true 3D micro parts made from polymer or ceramic materials with accuracy 
better than MEMS fabrication techniques such as soft lithography [23–27]. 
Several elements can affect the energy imparted by the laser, including the power of 
the light, the scanning rate, the material exposed and the quantity of both polymer and 
photoinitiator [5,17]. 
The main advantages of SLA 3DP technique are versatility, the production of 3D ob-
jects with a high resolution at room temperature, the minimised heating during the print-
ing process, absence of thermal degradation, which makes this technique more suitable to 
print dosage forms with thermally labile drugs included [5]. The principal drawbacks are 
the width of the focused layer, the reduced availability of biocompatible and biodegrada-
ble photocrosslinkable polymers, most materials are not recognised as GRAS, and the car-
cinogenic risk of the photopolymerising material [5,11,27,28]. Moreover, other limitations 
are the solubility [29], the stability of the drugs under UV light, which could be restricted 
and to avoid it, Kadry et al. suggested that it is relevant to carefully select the drugs and 
the necessity of both remove non-polymerised resin and post-curing [30]. 
The last technique evaluated was SLS, which is one of the most recent industry tech-
nologies used to prepare personalised solid dosage forms, either with immediate or mod-
ified drug release profiles. [18] It is a one-step, solvent-free method, where a laser beam is 
used to specifically bind powdered materials together and fabricate 3D structures layer-
by-layer [1,31]. Awad et al. defined this technique as economical, fast, and user-friendly 
[9]. 
SLS 3DP is a solvent-free process, which not implies an alteration of the properties of 
the polymers, and it allows the manufacture of printlets readily dispensable, which do not 
need to undergo a drying process at the end of the printing [31]. Moreover, SLS is charac-
terised by very good flexibility, which leads to the production of a broad range of dosage 
forms, with a huge variety of geometries and drug release profiles [9]. 
The principal advantages of SLS 3DP technique are its flexibility, allowing the pro-
duction of a broad range of dosage forms, characterised by several shapes and drug re-
lease profiles, the sintering process, which fused drug and polymer particles, forming a 
strong bond between the two elements, the high resolution of the laser beam, which al-
lows the formulation of very small and detailed units. Moreover, another relevant ad-
vantage is the high control of both the composition and the content distribution in the 
formulations [9]. Indeed, to fabricate these 3D structures is employed a high-resolution 
laser, which allows the realisation of high detailed objects, with a controllable internal 




structure. Moreover, this high precision also leads to a specific control of both the compo-
sition and the internal structure and thanks to these two elements, SLS is defined as an 
accurate and reproducible system [7,14]. Subsequently, once the printing end, the unsin-
tered powder can be removed by airbrushing or sieving and be reused, to reduce the wast-
age and promote the recycling of the feedstock [14]. It can be also defined as a cost-effec-
tiveness technology, because compared to the others, SLS resulted to be more economical. 
An initial limitation of this technique was the degradation of the drugs because it was 
used a CO2 laser, which worked in the IR region of the spectra, but, nowadays, are used 
diode lasers with a lower intensity and no more drug degradation occurs again [1]. Fur-
thermore, the commonly used materials are powdered forms of metal alloys, ceramics, 
and plastics, which need high temperatures values and high-energy lasers to be sintered. 
Indeed, these conditions limit the use of this technology into the pharmaceutical fields 
because the high-energy input of the laser can cause the degradation of the drugs if used 
as starting materials. Considering these limitations, SLS printing process is principally 
employed in the formulation of drug delivery devices, where the drug was already in-
cluded or for tissue engineering scaffolds [11]. 
The aim of this systematic review is to identify which type of 3DP techniques is the 
most suitable for printing of oral solid drug delivery systems. 
2. Materials and Methods 
To carry out the first stage of the systematic review (Figure 2), which was the general 
screening of the articles, five electronic databases were used (PubMed, Google Scholar, 
British Library, Europepmc, Web of Knowledge). For the article screening, some specific 
keywords were used which can be divided into two categories. The first one is related to 
the different techniques which can be used in the three-dimensional printing: “three-di-
mensional printing”, “Additive Manufacturing”, “Fused Deposition Modeling”, “Extru-
sion-based 3DP”, “Selective Laser Sintering”, “Stereolithography”, “Inkjet 3DP” and their 
acronyms “3DP”, “AM”, “FDM”, “SLS”, “SLA”. The second group of keywords focused 
on the different 3DP applications; “personalised medicines”, “oral formulations”, “solid 
formulations”, “oral and solid drug delivery systems”, “tablet”, “capsules”. The search 
phrase used as input in all the electronic databases was one of the keywords reported 
above or their combination. In particular, the research on PubMed was conducted also 
considering the sections named “Similar articles” and “Cited by”. 
In this systematic review, after the general screening of the articles, there was the 
formulation of a research question, which was “which type of 3DP technique is more suit-
able for printing oral and solid formulations” and the consultation of the international 
database “PROSPERO”, created by the University of York and funded by the NIHR (Na-
tional Institute for Health Research), an online portal for the registration of any intention 
to carry out a systematic review. The main aim of this portal is to make the systematic 
review known before it is developed, to reduce their unplanned duplication through the 
creation of a comprehensive listing of systematic reviews. Furthermore, it also allows 
readers to compare different systematic reviews and highlights the several outcomes and 
how they could affect the results of the planned systematic review. In this study, the NIHR 
portal was used to determine whether similar systematic reviews have been carried out, 
a selection of pre-defined inclusion and exclusion criteria was outlined to determine 
which articles were to be accepted [32]. 
The pre-defined inclusion criteria were (1) 3DP techniques and (2) solid oral formu-
lation while the exclusion criteria were (1) conventional techniques and (2) non-oral drug 
delivery systems. Moreover, only original research publications were included in the 
study, and other articles such as literature reviews, review articles, opinion articles and 
editorials were non-included. 




During the data extraction process, there were a particular focus on some relevant 
aspects, which were (1) year of publication, (2) technique used, (3) formulation, (4) char-
acterisation tests, (5) type of disease treated, (6) name of the drug and (7) aim. 
 
Figure 2. Different stages to carry out the systematic review: (1) general screening; (2) formulation 
of the review question; (3) definition of the inclusion and exclusion criteria and the keywords; (4) 
development of a research strategy; (5) research of articles using electronic databases; (6) evalua-
tion of the validity; (7) extraction of the data; and (8) analysis of the data. 
3. Results 
3.1. Included and Excluded Articles 
The number of articles that were reported to have used 3D printing in designing oral 
solid formulations has increased over the years (Figure 3). In 1999, 2 articles were pub-
lished. The number increased to 23 in 2014 and 91 to 2019 (green line). 





Figure 3. The number of 3D printed oral solid formulations published between 1999 and 2020 (green) and the number of 
articles included in the systematic review over the same period (blue). 
Majority of the articles were excluded, 74% (n = 376) as they did not meet the inclusion 
criteria. Some of these articles were found to have used conventional techniques (n = 111), 
such as solvent casting, direct compression, or wet granulation. Other articles were either 
about non-oral formulations (n = 5) or duplicate studies (n = 18) and therefore have not been 
included. The number of articles included in the systematic review was 26% (n = 131) (Figure 
4). 
 
Figure 4. The number of articles included (dark grey) and excluded (light grey) in the systematic 
review, following the pre-defined inclusion and exclusion criteria. 
3.2. 3DP Techniques to Print Oral and Solid Formulations 
Several 3DP techniques have been reported for the printing of oral solid formulations 
(Figure 5). FDM, known also as FFF, was the most used 3D printing technique, as it was 









most frequently used technique was the inkjet 3DP, which was reported in 13% (n = 14) of 
the studies. Other 3DP technologies considered in the systematic review, were SLA (7%, n 
= 9) and SLS (4%, n = 6). 
 
Figure 5. Quantification of the four 3DP techniques used in the articles included in the systematic 
review, (1) FDM (purple), (2) SLS (green), (3) SLA (yellow) and (4) inkjet 3DP (red). 
Some of the characterisation tests for tablets set by the British Pharmacopeia (BP) 
including drug content, uniformity of weight, disintegration, dissolution profile, friabil-
ity, and hardness tests were carried out to evaluate the effectiveness of each technique in 
some of the studies. Characterisation test results were compared to limits and standards 
recommended by the BP. The acceptance value for uniformity of weight depends on the 
drug content while that of uncoated tablets disintegration time is within 15 min in water 
(authors should consider the BP general tablet monograph for coated tablets). For in vitro 
dissolution profile, a 70% drug release within 45 min is considered acceptable and for 
friability test, a weight loss of ≤1% for 10 tablets spun at 25 rpm for 100 turns (rotate 10 
tablets at 50 rpm for 10 min) is recommended. Hardness is generally equal to 10–15 kg 
which is equal to 100–150 N. It is relevant to undergo these tests to determine if the 3DP 
oral and solid formulations respect the limit defined by the British Pharmacopeia [33]. 
Authors should discuss the results and how they can be interpreted from the per-
spective of previous studies and of the working hypotheses. The findings and their impli-
cations should be discussed in the broadest context possible. Future research directions 
may also be highlighted. 
3.3. Inkjet 3DP 
Characterisation Tests 
In the systematic review 14 articles were included, where Inkjet 3DP printing was 
used to manufactured oral solid formulations, which most of them were in the form of 
tablets (86%, n = 12). 
The drug content was evaluated in 93% (n = 13) of the included publications. For 
instance, Clark et al. obtained a drug content equal to 97 ± 0.4% and they reported that 
there was a percentage recovery, possibly due to a small amount of degradation of the 
API or due to an incomplete drug release from the tablets. By contrast, Cader et al. 
achieved a drug content of 39.8%, closed to the theoretical one of 38.4%, which was calcu-
lated considering the composition of the solid components of the formulation of the ink 
[19,20]. 
SEM analysis was carried out in 50% (n = 7) of the included articles. In the work con-
ducted by Yu et al., it was analysed the inner structure of the tablets and it was observed 
that PVP particles did not have a regular shape, because PVP was an amorphous polymer, 




instead, the drug included, paracetamol was always present as a large prismatic white 
crystal. Moreover, the printed regions resulted were bound together through a dissolu-
tion-reprecipitation mechanism and the drug particle size was decreased, and the indi-
vidual particles could not be more distinguished. Instead, in the unprinted regions, the 
drug particles maintained their original shapes, showing cracks and fissures [34]. Addi-
tionally, in the work done by Sen et al., the SEM analysis was performed, and it was re-
ported an external rough structure of the tablets, with numerous porous gaps or voids on 
the surface [35]. 
The drug dissolution profile was evaluated in 93% (n = 13) of the articles included and 
54% of the 3DP formulations showed an immediate drug release, instead 46% a sustained 
drug released. Clark et al. reported that 80% of the drug was released within 10 h and a 
complete drug released was achieved within 20 h. The main parameter which affected the 
drug release was the table shape. Moreover, the authors observed that a faster release was 
correlated to an increase of the SA/V ratio of the geometries, where the thin layer had the 
faster dissolution profile and the cylinder one, with the slowest one. Furthermore, this 
correlation between the drug release profile and the shape was also noticed by Lee et al., 
who also observed that the geometry of the microparticles affected several elements, such 
as degradation rate, stability, and drug release profile. Furthermore, the degradation of 
the microparticles was inversely proportional to the surface area and dimension [36]. By 
contrast, Sen et al. obtained an immediate drug release profile, where more than 80% of 
the drug was released within 30 min [29]. Considering the BP specifications, only in the 
work conducted by Sen et al., were met the BP limitations. 
Four of the BP specifications required during the manufacturing process are the hard-
ness, friability, disintegration time and uniformity of weight. Hardness was measured in 
14% of the articles (n = 2) and the values were reported with different units. Sen et al. 
manufactured tablets with hardness values equal to 3.6–5.0 kg/cm2, instead, Yu et al. 
measured values of 63.4 ± 5.4 N/cm2 [28,29]. Furthermore, friability was determined in 
21% of the publications (n = 3). In the work published by Infanger et al. the value of fria-
bility was directly proportional to the porosity of the binder particles [36]. For instance, 
smaller particles had values of 0.94–0.95%, which are within the BP pharmacopoeia spec-
ifications. Similar values were obtained by Sen et al., with a friability of less than 0.87% 
[34]. 
Considering the two other BP specifications, the disintegration time was measured in 
29% articles (n = 4). Infanger et al. noticed that the disintegration time was affected by the 
binder viscosity. For instance, the viscosity of SL was twice than the one of SSL-FP and in 
the first case, the disintegration time was 1457 ± 553 s, instead the other was equal to 131 ± 
71 s. This double value of viscosity led to the creation of a viscous layer before a full tablet 
disintegration. Moreover, this also caused long disintegration times because these newly 
formed gel matrices showed slow erosion, instead, the lower binder viscosity during water 
ingress allowed a faster absorption and a quicker disintegration [18]. Alomari et al. and 
Wilts et al. registered a disintegration time of 43 s and 30 s, respectively, suggesting that the 
manufactured tablets were classified as ODTs. Moreover, all these formulations met the BP 
specifications, having a disintegration time of less than 15 min [2,37]. 
By contrast, considering the uniformity of weight, it was evaluated in 43% (n = 6) of 
the publications. For instance, in the study conducted by Clark et al., were reported two 
values, one related to the batch a and the other to the batch b, which were 14.31 ± 0.04 and 
14.17 ± 0.03, respectively. Furthermore, with batch a, the percentage deviation was 0.56%, 
whereas with batch b was equal to 0.42%. Considering the average mass, the percentage 
deviation, and the Pharmacopeia requirements, it was possible to conclude that both 
batches met the specification [20]. 




3.4 FDM (Fused Deposition Modeling) 
Different 3DP drug delivery systems were realised using FDM as 3DP technique, (Fig-
ure 5), where tablets were the most common manufactured formulations, as it was reported 
in 67% (n = 69) of the FDM articles. Furthermore, another frequently reported formulation 
were capsules, which were the second most frequently 3D formulation manufactured by 
FDM, with a percentage of 17% (n = 17). Other 3DP formulations produced with this 3DP 
technology were filaments (5%, n = 5), films (5%, n = 5), discs (3%, n = 3), matrices (2%, n = 
2) and mouthguard (1%, n = 1). 
 
Figure 5. Representation and quantification of the main 3DP formulations manufactured using 
FDM 3DP technique, (1) tablets (red), (2) capsules (dark green), (3) filaments (blue), films (yellow), 
discs (pink), matrices (black) and mouthguard (light green). 
Tablets were more produced due to better physical-mechanical properties, such as 
hardness, friability, and hardness, which in most of the cases, met the British Pharmaco-
peia specifications. 
3.4.1. Characterisation Tests 
Different characterisation tests were performed to evaluate the physical-mechanical 
properties of the FDM 3DP formulations. (Figure 6) Moreover, each test was carried out 
to study specific factors and properties, such as the disintegration time, the breaking force 
of a tablet, the drug release profile, the 3D structure, the porosity and if during the 3D 
printing occurred the degradation of the drug(s). 





Figure 6. Quantification of the number (%) of FDM articles where the different characterisation 
tests, (1) uniformity of weight, (2) disintegration, (3) friability, (4) hardness, (5) dissolution test, (6) 
SEM and (7) drug content, were performed following the British Pharmacopeia specifications. 
The drug content test was carried out in 68% (n = 69) of the articles included in the 
systematic review and, in most of them, was achieved a value of drug content closed to 
the theoretical one, indicating an absence of drug degradation during the FDM process. 
For instance, in the work conducted by Genina et al., the theoretical content was 70% w/w 
and the actual drug content was equal to 62.2 ± 1.4% and the authors suggested that this 
little difference was due to the stickiness of the drug, in the form of powder, during the 
manufacturing process [38]. By contrast, Goyanes et al. observed that half of the drug (4-
ASA) degraded at 210 °C, which was the temperature of the heated extruder. The initial 
drug content was 0.24% w/w and after extrusion, was equal to 0.12% w/w. 4-ASA melted 
and decomposed at a temperature within 130–145 °C. This suggested that it was relevant 
to select the appropriate drug, based on its physical properties [39]. 
As reported in Figure 6, SEM analysis was performed in 77% (n = 79) of the included 
articles and the results differed. For instance, Skowyra et al. observed, at the end of the 
extrusion process, the formation of irregular pores on the surface of the extruded filaments 
and voids between layers, due to the evaporation of the water content and evaporable 
additives. Moreover, the surface appeared irregular and rough with partially fused fila-
ments [40]. Moreover, in a second work conducted by Goyanes et al., it was reported that 
the internal patterns were influenced by the infilling percentage. In fact, with a higher 
infilling percentage, the tablets appeared denser [41]. 
The most frequent characterisation test in the FDM articles included in the systematic 
review, was the dissolution test (Figure 6), performed in 97% of the articles (n = 99) to 
evaluate the amount of time necessary to a drug to dissolve in the dissolution media and 
if the drug release profile was immediate or sustained (Figure 7). 





Figure 7. Representation of the two different drug release profiles, (1) sustained drug release 
(blue); (2) immediate drug release (green), which are shown by the 3DP formulations in the in-
cluded FDM studies. 
Most of the 3DP formulations presented a sustained drug release (73%, n = 70) had a 
sustained drug release profile and as defined by many authors, the drug dissolution pro-
file can be affected by several factors. For instance, Shin et al., Tagami et al., observed that 
it was affected by the shape and by the size of the 3DP formulations. Moreover, smaller 
tablets had a quicker drug release due to a larger surface area/mass ratio, whereas larger 
tablets, defined also as printlets, presented a slower drug release because the SA/V ratio 
was smaller [42,43]. For instance, Skowrya et al. noticed that majority of the drug (>80%) 
was released after 12 h and over 18 h with doses equal to 4, 5, 7.5 and 10 mg. Moreover, 
the complete drug release was achieved within 16 h for smaller tablets and within 20–24 
h for bigger ones, due to a smaller SA/V ratio [44]. The BP acceptance limit was met only 
by formulations with an immediate drug release profile. 
Another important British Pharmacopeia specification was the hardness test, which 
was conducted in half of the included studies (51%, n = 52) (Figure 6). Moreover, this re-
duced evaluation could represent a limitation, being one of the specifications required by 
BP. In some cases, this parameter was not evaluated, because the hardness strength of the 
tablets was bigger than the maximum values measurable by the hardness tester (800 N), as 
in the work conducted by Goyanes et al. [41] and Chen et al. [45]. On one hand, the 3DP 
FDM formulations presented reduced values of hardness, such as, in the work performed 
by Khaled et al., the mesh tablets had values of 24.67 N and ring tablets of 24.72 N and In 
both cases, the hardness values were too small [45,46]. 
On the other hand, Okwuosa et al. obtained a crushing strength bigger than 350 N 
and Pietrzak et al. more than 490 N, indicating that the manufactured tablets presented 
great hardness properties, which met the British Pharmacopeia specifications [47,48]. Con-
sidering the four articles reported as an example, only the last two performed by Okwuosa 
et al. and Pietrzak et al. met the specifications, instead, the other two failed. 
A third BP requirement was represented by the friability test, which was carried out 
only in 24% of the FDM included articles, possibly due to the reduction of the hardness 
values of the formulations. Moreover, considering the publications where this analysis 
was performed, all of them met the BP requirements, having a friability parameter minor 
or equal to one [48]. In some cases, the friability was 0%, such as in the works conducted 
by Okwuosa et al. and Goyanes et al. [41,49]. 
The fourth BP specification is the disintegration time; considering Figure 6, this test 
was performed in only 18% (n = 18) of the articles, and as reported for the friability, this 
can represent a limitation and an aspect that should be analysed more in future works. 
Taking in account the articles where the disintegration time was evaluated, only in few 
cases, it was possible to define the formulation as an ODT (complete disintegration un-
derwent in less than 3 min (European Pharmacopeia) (or if less than 30 s by the FDA), 




such as in the works conducted by Jeong et al. and Khaled et al. [46]. In the other cases, 
the complete disintegration time was in a range within 5 and 15 min and in all these arti-
cles, the BP specification was met. Moreover, Palekar et al. noticed a direct correlation 
between the infill percentage and the disintegration time. In fact, with a higher infill per-
centage, more the water penetration in the formulation was reduced and faster was the 
disintegration time [50]. 
Last, but not least BP requirement to take in consideration, was the uniformity of 
weight, whose acceptance range depended on the average mass. For instance, if the aver-
age weight was 84 mg or less, the maximum deviation percentage was 10%, if the weight 
was between 84 and 250 mg, a deviation percentage of 7.5, instead of the average weight 
was more than 250 mg, it is accepted a deviation percentage of 5%. Analysing the above 
chart (Figure 6), it was reported that this test was done in 57% (n = 58) of the included 
articles and only in some of them the BP limitations were respected. For instance, on one 
hand, in the work conducted by Li et al., were manufactured three different tablets, with 
three different infilling percentage (30%, 50% and 70%) and in all the three cases, the de-
viation percentage was 2% and the average weight bigger than 250 mg, it was possible to 
define that all the formulations met the specification [50]. On the other hand, Okwuosa et 
al. obtained deviation percentages of 15.2% and 9.54% and has an average weight between 
84 and 250 mg, both formulations did not meet the BP specifications [49]. Moreover, the 
same result was achieved by Goyanes et al. having a deviation percentage of 12% and an 
average weight more than 250 mg (309–348 mg) [51]. 
3.4.2. Drugs Classification 
Different drugs were reported to be included in the FDM 3DP formulations, Figure 
8, and their use depended on the type of disease to treat. Anti-inflammatory drugs, such 
as acyclovir and prednisolone, analgesic, as paracetamol and aspirin and anti-hyperten-
sive, such as nifedipine and carvedilol, were the most used type of drugs used included 
in the FDM 3DP formulations. 
 
Figure 8. Characterization and quantification of the main type of drugs used and included in the 
FDM 3DP formulations, (1) anti-psychotic; (2) antiplatelet; (3) anti-Parkinson; (4) antifungal; (5) 
analgesic; (6) anti-arrhythmic; (7) anti-cancer; (8) anti-diabetic; (9) anti-hypertensive; (10) anti-in-
flammatory; and (11) antibacterial. 
As defined in the initial part, one of the main limitations of the FDM technique was 
the drug degradation, due to the temperature of the heated nozzle, which is correlated to 
the melting temperature of the polymers. As suggested by some authors, as Goyanes et 
al. and others, to avoid this drug degradation during the extrusion process, it was relevant 
to select the appropriate drug(s) and polymers to use to manufacture the 3D objects, based 




on their physio-chemical and mechanical properties. To allow this, we decided to evaluate 
the melting temperature of the polymers used in the included articles and following these 
values, it would be possible to define the best drug(s) to include into the drug delivery 
system, without any risk of drug degradation [51]. 
3.4.3. Polymers Classification 
In the following SmartArt (Figure 9) the polymers were classified in three main cate-
gories based on the printing temperatures reported in the included publications, (1) less 
than 100 °C; (2) between 100 °C and 150 °C; and (3) more than 150 °C. Moreover, the print-
ing temperature is a relevant parameter, which needs to be defined every single time 
based on two parameters, the melting temperature of the polymer and the temperature at 
which the drug(s) will start to undergo the process of degradation. 
 
Figure 9. Classification of the polymers used with FDM 3DP technique based on three different printing temperature 
ranges: (1) T < 100 °C (green), (2) 100 °C ≤ T ≤ 150 °C (yellow) and (3) T > 150 °C (red). 
Some polymers were reported in multiple columns because they can be extruded at 
different printing temperature, which was defined considering some parameters, (1) deg-
radation temperature of the drug(s); and (2) melting temperature of the polymer(s). An 
example was PEG 6000, which can be printed within a range of temperature of 100–250 
°C and, Considering the work conducted by Khaled et al., 3DP tablets were realised using 
PEG 6000 and HPMC 2910 as polymers and nifedipine and captopril were included as 
drugs [52]. Moreover, as printing temperature was set a value of 60 °C, whereas, consid-
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Kempin et al. used PEG 6000 with other polymers to print at 100 °C 3DP immediate-re-
lease tablets containing pantoprazole sodium sesquihydrate [53]. Instead, analysing the 
last column, with a printing temperature more than 150 °C, the same polymer, PEG 6000, 
was used by Tan et al. to manufacture sustained-release theophylline caplets. Moreover, 
the drug included in these caplets was theophylline and as printing temperature was de-
fined as a value of 195 °C [54]. In all the three examples considered, the drugs did not 
undergo a process of drug degradation, suggesting that the defined printing temperature 
was appropriate and did not lead to a reduction of drug content after the printing process. 
Around 19% of the included articles used temperatures below 100 °C. For instance, 
gastro-floating tablets were manufactured by Lin et al. using dipyridamole as drug and 
HPMC as polymer and the printing process was set at a temperature of 23 °C [48]. Simi-
larly, Khaled et al. used the same printing temperature to formulate high drug loading 
immediate-release tablets, containing paracetamol as a drug, and as polymer was utilised 
PVP K25 [46]. 
Moreover, approximately 32% of the included publications had a printing process 
temperature within 100 and 150 °C. For instance, Chen et al. manufactured 3DP ellipsoid 
shaped gastric-floating tablets at 142 °C, using PVA as polymer and including propanol 
hydrochloride as the model drug [43]. In a second article, Kimura et al. realised zero-order 
sustained release floating tablets, using a poorly water-soluble weak base drug, itracona-
zole and as polymers, HPMC (hydroxypropyl cellulose) and PVP (polyvinylpyrrolidone) 
at a printing temperature of 135 °C [54]. 
By contrast, in around 52% of the FDM articles, was used a printing temperature 
above 150 °C to formulate oral and solid drug delivery systems. Moreover, the printing 
temperatures varied from 155 °C to 250 °C and there was a higher risk than the other range 
of temperatures, that the drug included in the formulation underwent a degradation pro-
cess, due to the high extrusion process temperature. An example of this limitation was 
reported in the article conducted by Goyanes et al. 4-ASA and 5-ASA were used as model 
drugs and PVA as polymer, where only 4-ASA, whose degradation temperature was 
within 130–145 °C, was affected by the drug degradation, which was noticed by a reduc-
tion of the drug content from the beginning to the process (0.24% w/w) and the end (0.12% 
w/w). Furthermore, the authors reported that 5-ASA did not degrade because the printing 
temperature (210 °C) was lower than the one of its degradation point and also suggested 
that even if the residence time was short inside the print head, around few seconds, ther-
mally labile drugs can undergo a significant degradation and this limitation could be over-
come using a lower temperature [38]. By contrast, in other articles, such as the one con-
ducted by Skowyra et al., extended-release patient-tailored tablets were realised setting a 
printing temperature of 230 °C, using PVA as polymer and prednisolone as a model drug 
[40], or the one performed by Jeong et al., where gastroretentive sustained-release cap-
sules were printed at 220 °C, using PLA as polymer and baclofen as a drug, no drug deg-
radation was observed during the printing process because the actual drug content was 
closed to the theoretical one [55]. 
3.5. SLA (Stereolithography) 
Considering the eight included articles in the systematic review, all the 3D formula-
tions were printlets (100%, n = 8). Moreover, the authors observed different structures 
based principally on the type of excipients. 
The drug content was evaluated in 100% of the included articles (n = 8) and all the 
authors agreed that during the printing process, there was not any drug degradation. 
Moreover, the little difference between the drug loading value and the theoretical one was 
possibly due to an incomplete drug degradation from the drug-polymer matrix [5,11,30]. 
For instance, Wang et al. obtained a drug loading of ±5.83% w/w, which was like the 
theoretical one (5.9% w/w), suggesting the absence of drug degradation [5]. Same results 
were achieved by Martinez et al. and Kandry et al. Moreover, in the first case, the average 




drug content in the tablets, 3.82 ± 0.12% w/w was closed to the theoretical value of 4% w/w, 
which was calculated based on the formulation of the resin [10]. Furthermore, Kadry et al. 
had values of drug content within the range 97.18–98.75%, which respected the specified 
by the British Pharmacopeia. Moreover, the authors confirmed the absence of drug deg-
radation undergoing and evaluating the UPLC spectrum [30]. Moreover, Martinez et al. 
evaluated the drug content inside the polypills, using HPLC and the results demonstrated 
that the drug loading had a range between 85–104%, which was within the acceptable 
range for content uniformity (85–115%) defined by the British Pharmacopeia [56]. 
To look at the characteristics of the printed tablets, 37.5% (n = 3) used SEM to evaluate 
the inner structure and the total porosity of the printlets and the results obtained differed 
based on the type of excipient(s) used. For instance, in the work conducted by Healy et al. 
was noticed an absence of voids on the surface of the dosage forms, which was an indica-
tion of the high level of curing. Moreover, considering the cross-sectional images of the 
tablets, the authors observed the absence of a homogeneous distribution of either drug 
and/or photoinitiator within resin, probably due to an incomplete dissolution or agglom-
eration process [18]. 
Similarly, Kandry et al. observed tablets with a smooth surface and the additive char-
acteristics of the layer-by-layer of 3DP, where each layer had a thickness equal to 200 µm. 
Furthermore, to print these formulations, the authors did not use SLA, but DLP (Digital 
light processing), a similar technique, which differed for the light source to cure the resin. 
Indeed, the SLA uses lasers combined to galvanometers, instead DLP, the light source was 
represented by a digital light projector screen. Kandry et al. defined this 3DP technique as 
having a superior capability to print tablets, with uniform weights and dimensions [30]. 
By contrast, Krkobabić et al. noticed a variation of the internal structure of the 
printlets based on the presence or absence of excipients. For instance, when PEG 400 was 
used, the authors observed a crack propagation during the dissolution test, which had a 
role in the printlets erosion. Moreover, another example was represented by mannitol, 
which caused the formation of an irregular internal structure. Indeed, considering the 
cross-section of the tablets after the dissolution test, it was possible to see cracks, which 
indicated that tablet capping under elevate pressure, determined by the osmotic effect of 
mannitol [57]. 
Another important test that was conducted to evaluate the effectiveness of SLA tech-
nique, was the drug dissolution test, which was performed in 100% (n = 8) of the articles. 
In particular, the authors evaluated the correlation between several parameters, such as 
the ratio between cross-linkable polymers in the tablets, the structure of the tablets, their 
geometry, and the addition of excipients on the drug release rate. The authors concluded 
that it was relevant to select the suitable amount of photocrosslinkable polymer to manip-
ulate the drug release rate and that both the geometry of the tablets and the addition of 
excipients can affect the dissolution profile. 
Wang et al. evaluated how the ratio between the cross-linkable polymers in the tab-
lets, PEDGA/PEG 300 could affect the dissolution profile. On one hand, they observed an 
indirect correlation between the amount of PEDGA and the drug release rate. For instance, 
when the amount of PEDGA was equal to 35%, 100% of paracetamol was released after 
10 h, whereas, when it was 65% and 90%, the quantity of paracetamol released was 84% 
and 76%, respectively. On the other hand, the correlation between the amount of PEG 300 
and the drug release rate was direct, indicating that with an increase of the first, there 
would be an increase of the second [5]. Moreover, in an experiment conducted by Heavy 
et al., it was also highlighted the relation between cross-linkable polymers and drug re-
lease rate. Additionally, these authors, as did Wang et al., concluded that it was relevant 
to select the suitable photocrosslinkable polymer to manipulate the drug release, because, 
on one hand, if the amount of polymer were too low, there could be surface cure problems. 
On the other hand, if it was too high, this concentration could reduce the amount of UV 
light that would penetrate through the lower layers, determining inadequate curing. 




Moreover, the formulations were characterised by a sustained drug release rate profile 
over the 24 h [18]. 
Similarly, Martinez et al. analysed the effect of the geometry of the printlets and the 
addition of excipients on the dissolution profile, realising three types of printlets. In the 
case of type I, a cylindrical printlet, it did not reach a complete drug release rate after 20 
h, but it was within a range of 22–80%. Instead, type II, a ring-shape tablet, presented a 
faster drug release, because there was an increase of the surface area. Furthermore, the 
third type of polypill was realised to evaluate how a soluble filler (solubilising agent), PEG 
300, can modify the dissolution. Indeed, the authors observed that its addition, led to an 
improvement of the drug release rate, compared to the type I, and the increase was af-
fected by the type of drug. For instance, with paracetamol and aspirin, it was reached a 
complete drug release in 20 h, instead, with prednisolone, a poorly soluble drug, was in-
creased to 45%, but it was never achieved a complete drug release after 20 h [56]. 
The hardness, defined also as breaking force, is an indicator of the mechanical prop-
erties of the tablets, was evaluated in 37.5% of the studies (n = 3) and one of these articles, 
the authors noticed that the hardness and the tensile strength were affected by the number 
of excipients, such as PEG 400, PEDGA, water and mannitol. 
In the study conducted by Madzarevic et al., eleven different formulations were man-
ufactured, with a different composition (% w/w) in terms of the amount of PEGDA, PEG 
400, Water, riboflavin, and ibuprofen. For every single formulation was calculated the 
hardness values and based on their hardness values, the formulations can be classified 
into two categories, (1) met the British Pharmacopeia requirement, having a hardness 
value between 100 and 150 N, instead (2) did not meet the BP requirements, because the 
values were lower than 100 N. Seven of the eleven formulations did not meet the specifi-
cations, because their hardness values were between 19.00 ± 8.66 N and 47.33 ± 3.21 N. 
Instead, formulation number 3, 4, 6 met the BP specifications, having a hardness value 
within the range of 92.33 ± 29.02 N and 132.33 ± 18.88 N, whereas with formulation num-
ber 7 the hardness was not determined [28]. 
Another characterisation test required by the British Pharmacopeia was the uni-
formity of weight, which was evaluated in 50% (n = 4) of the studies. In the work con-
ducted by Heavy et al., the weight uniformity of all the printlets had a range between 
81.7–118%, with a percentage deviation of 36.3% and, considering that the average mass 
was 1621 mg and the prescribed limit of weight varies according to British Pharmacopeia, 
these values did not respect the prescribed limits [19]. 
Similarly, in the publication carried out by Kadry et al., the weight of the tablets was 
between 133.70 mg and 174.23 mg. The average weight was 154.0 mg and the range was 
86.8–113%, with a difference of 26.2%. Considering the prescribed limits of weight varia-
tion set by the British Pharmacopeia, these tablets did not meet the Pharmacopeia Speci-
fications [30]. Both formulations did not meet the Pharmacopeia requirements, having a 
percentage of deviation bigger than the one defined by the British Pharmacopeia. 
3.6. SLS 
To carry out the systematic review were considered 6 articles (4%) of the included 
publications. The drug content, determined by HPLC analysis, was evaluated in the major 
part of the included publications, 83% (n = 5), and, in all these articles, the authors reported 
and agreed that no drug degradation, defined also as drug loss, occurred during the SLS 
printing process because the drug(s) content was close to the theoretical value 
[1,7,12,15,31]. For example, Allahham et al. quantified the drug loading of the printlets 
and they obtained that it was very close to the theoretical values. In the case of formulation 
one, the drug loading value was equal to 98.6% ± 2.2, instead, with formulation two was 
to 98.1% ± 1.7 [1]. 
Similarly, in the study conducted by Fina et al., it was demonstrated that no drug(s) 
degradation occurred during the SLS printing process and to confirm it, the drug content 




was determined and in all the cases, the values were closed to the theoretical drug loading 
(5, 20 and 35%). Moreover, another element to highlight their theory was considering the 
HPLC spectrum and if no other peaks than the ones of the drug were observed, this indi-
cated that no drug degradation occurred. This is what the authors noticed during their 
work [11]. 
SEM analysis was performed in 83% (n = 5) of the included articles and the authors 
noticed an indirect correlation between two parameters, the laser scanning speed and the 
total porosity of the tablets, a correlation between the structure of the printlet and the 
intensity of the sintering process and between the structure of the printlet and the type of 
excipient added, such as mannitol. 
Fina et al. observed the indirect correlation between the laser scanning speed and the 
porosity values of the printlets. Indeed, with an increase of the speed from 100 to 300 
mm/s, there was a decrease of the sintering of powder particles, and this led to an increase 
of the overall porosity, which, respectively, determined an improvement of the disinte-
gration and dissolution of the printlets [31]. 
On contrast, Awad et al. noticed the correlation between the structure of the printlet 
and the intensity of the sintering process. The single miniprintlets underwent a more in-
tense sintering process, whereas the dual miniprintlets, had a low-intensity sintering pro-
cess, which led to the creation of a higher space volume within the particles [5]. In another 
work, Fina et al. highlighted the influence of different formulations on the total porosity 
values. For instance, Kollicoat formulations had similar porosity values, instead, Eudragit 
dosage forms presented a reduction of the total porosity, directly proportional to the in-
crease of the drug content [12]. 
The drug dissolution profile was evaluated in all 100% (n = 6) of the included articles. 
The authors reported that the drug release rate was affected by several factors, such as 
formulation, laser scanning speed, the structure of the tablet (single miniprintlets or dual 
miniprintlets), shape and open porosity [31]. 
Fina et al. demonstrated that the drug release rate was influenced by the laser scan-
ning speed. Indeed, three different laser scanning speeds were tested and the correlation 
between the laser scanning speed and the drug release rate depended on the formulation. 
For instance, HPMC formulations showed a decrease of the dissolution rate with an in-
crease of the laser scanning speed (100 mm/s = 4 h, 300 mm/s = 2 h). Whereas Kollidon 
formulations presented a direct correlation between drug release rate and laser scanning 
speed (100 mm/s = 60 min, 200 and 300 mm/s = 10 min). Moreover, both formulations had 
an immediate drug release profile [31]. 
Furthermore, both Awad et al. and Goyanes et al., in their respective studies, noticed 
that the drug dissolution profiles were influenced by the structure of the tablets. On one 
hand, Awad et al. observed that single miniprintlets shows a sustained-drug release, 
where after 24 h about 71% was released, instead, the dual miniprintlets had an immediate 
drug release profile, undergoing a complete drug release in 30 min. On the other hand, 
Goyanes et al. formulated two different types of printlets, cylindrical and lattice. In both 
cases, 4 excipients were used and based on the type of printlet, they showed a different 
drug release, sustained for the cylindrical ones (for instance, PEO formulation released 
60% of the drug in the first 2 h and the rest, 40%, in the following 4–5 h) and immediate 
for the others (such as PEO underwent a complete drug released in 10 min) [15]. 
Similarly, Fina et al. noticed the correlation between the drug release rate and both 
drug content and porosity values. Indeed, Kollicoat formulations, with an immediate 
drug release profiles, had an improvement of the drug released based on an increase of 
the drug content. For instance, K5 took 5 h to dissolve completely, whereas K35 approxi-
mately 5 h. On the other hand, the drug release profile of Eudragit formulations was in-
fluenced by both the drug content and the porosity values. Indeed, in 2 h, E5, with the 
highest porosity values, released 14% of the drug, instead of E35, with a reduced porosity, 
released only 6% of the drug [21]. 




The hardness of the printlets was evaluated in 83% of the articles (n = 5). Some au-
thors highlighted the indirect correlation within the laser scanning speed and the breaking 
force values, such as Fina et al. In the articles included, more than half of the manufactured 
tablets were characterised by a reduced hardness and this can represent a limitation. 
Fina et al. noticed the correlation between the laser scanning speed and the breaking 
force values. For instance, 3DP printlets manufactured at higher laser scanning speed had 
a value equal to 14 N (weak), instead, the ones realised at a lower speed, presented a 
breaking force value of 171 N (strong) [26]. Moreover, Allahham et al. manufactured two 
different formulations of printlets, which differed for the percentage of excipients and 
they both showed similar breaking force values, 14.7 N and 18.5 N. Moreover, the authors 
reported that these dosage forms did not break readily during the manipulation process 
and due to this, they presented appropriate properties for handling [1]. 
By contrast, in the work conducted by Goyanes et al., the three cylindrical printlets 
were strong, having a breaking force value of 280 N. On one hand, the lattice printlets of 
EUD L and EC were more friable, having a breaking force value of 15 N. On the other 
hand, the lattice tablets of EUD RL broke into small pieces during the test and due to this 
reason, it was impossible to detect their breaking force values. The breaking force values 
depended on both the type of printlets (cylindrical and lattice) and the typology of excip-
ient (PEO, EUD L, EC or EUD RL) [39]. Moreover, in this experiment, the manufactured 
printlets were characterised by a high hardness. 
The friability values were calculated in only 17% (n = 1) of the included studies and 
Fina et al. registered values less than 1% (range values 0.02–0.53%), which met the BP 
requirements for uncoated tablets, making them suitable for handling and packing [12]. 
Another relevant test carried out to evaluate the printlets properties was the disinte-
gration test, which was done in 67% (n = 4) of the included studies. In the work conducted 
by Fina et al., three formulations were manufactured, and the authors noticed that with 
an increase of the laser scanning speed was correlated to a decrease of the disintegration 
time. For instance, the formulation realised at 100 mm/s, showed a disintegration time of 
over 600 s, instead, the two manufactured at 200 and 300 mm/s, underwent a complete 
disintegration in 320 s and 4 s, respectively. Based on the definition of ODTs given by the 
European Pharmacopeia and FDA, only this last formulation (K300), can be defined as 
ODT. The authors suggested that this reduction was correlated to the less energetic sin-
tering process. Subsequently, this led the powder particles to get in contact with the dis-
solution medium and, the improved porosity values determined a reduction of the disin-
tegration time [31]. 
Moreover, other authors who produced ODTs formulations were Allahham et al. and 
they calculated that the printlets disintegration times of the printlets (15 s) were in line 
with the values of the commercial formulation (14.3 ± 2.7 s) [1]. Similar values were 
achieved by Awad et al., through the fabrication of printlets without any pattern or with 
Braille A and Q, and they obtained values equal to 4.0 ± 1.3 s for printlets without any 
pattern, 4.3 ± 1.5 s with Braille A and 5.2 ± 1.2 s for Braille Q [58]. 
By contrast, the only authors who did not manufacture ODTs, were Goyanes et al. 
were reported the disintegration values of only two printlets, PEO and EUD RL with a 
lattice structure. PEO showed a complete disintegration in 10 min, instead EUD RL within 
120 min. Following the definition of ODTs given by the European Pharmacopeia and 
FDA, neither of them could be considered an oral disintegration tablet [15]. 
The weight uniformity was evaluated in 67% (n = 4) of the included articles. The au-
thors noticed that it was influenced by several variables, such as the laser scanning speed 
and the types of formulations. It was observed an indirect correlation within the laser 
scanning speed and weight uniformity. 
Moreover, Fina et al. highlighted an indirect correlation between the laser scanning 
speed and the weight uniformity. Indeed, an increase of the laser scanning speed led to 
an arise of the number of necks inside each layer, to a reduction of the empty spaces and 




the formation of more spaces for powder particles to be sintered and this determined the 
manufacture of denser and heavier printlets [31]. 
Furthermore, in the work conducted by Awad et al. to produce 3D printlets with 
Braille and Moon patterns, the average weight of Braille printlets was 171.3 mg, with a 
range from 164.1 ± 1.6 mg (printlets with a one Braille dot) to 178.1 ± 5.6 mg (average 
weight printlets with 5 Braille Dots). The authors noticed an increase in the average weight 
of 3.8% with the addition of one Braille Dot. By contrast, the Moon printlets showed an 
average weight of 165.8 mg, with a weight range within 162 ± 1.7 mg (weight with letter 
H) to 171.1 ± 5.9 mg (average weight printlets with letter N) [58]. 
On one hand, the Braille patterns with a one Braille date, the uniformity of weight 
presented a range of 99–101%, with a percentage of deviation equal to 2%. Considering 
the Pharmacopeia requirements, it was possible to conclude that these tablets met them. 
On the other hand, the 5 Braille dots had a range equal to 96.9–103%, with a percentage of 
deviation of 6.1%. Considering the average mass and the Pharmacopeia requirements, it 
is possible to conclude that both tablets met the specification. Instead, considering the 
Moon patterns, the printlets with letter H had a percentage deviation of 2% (99–101%), 
whereas the ones with letter N, had a value equal to 6.4% (96.6–103%). Additionally, these 
printlets met the BP specification. 
4. Discussion 
This systematic review was carried out to determine which 3DP technique resulted 
as the most suitable to formulate oral solid drug delivery systems. As the first step, the 
articles were screened and 514 were selected based on both the keywords and on the re-
view question. Secondly, the publications were classified into two groups, included, or 
excluded, following the pre-defined inclusion and exclusion criteria. Based on this classi-
fication system, 26% articles (n = 131) were included and 76% (n = 376) were excluded 
(Figure 3). 
The initial study was focused on quantifying which of the several 3DP techniques 
evaluated, occurred more often in the included publications and as reported in Figure 4, 
FDM, with a value of 76% (n = 102), was the 3DP technique most used to formulate oral 
solid drug delivery systems. Moreover, the main advantages of this technology were a 
high resolution, good mechanical strength, and the possibility to manufacture 3D formu-
lations with a specific drug release profile, obtained varying some printing parameters. 
By contrast, as reported in the data analysis chapter, one the biggest challenges of FDM 
technique was the degradation of the drug, due to the selection of a printing temperature 
above the degradation point of the drug, causing deterioration of its mechanical proper-
ties and reduction of the drug content. Furthermore, considering how relevant was this 
parameter in the FDM printing process, the polymers, as reported in Figure 8, were clas-
sified into three different categories, (1) T < 100 °C, (2) 100 °C ≤ T ≤ 150 °C, (3) T > 150 °C. 
The third category represented the one where the degradation of the drug(s) included in 
the 3DP formulations could occur more often, due to the use of a high printing process, 
defined also as extrusion temperature of the nozzle in the print head. The degradation of 
the drug is a relevant drawback of FDM because it does not allow the inclusion of thermo-
sensible drugs inside the filaments, such as 4-ASA. 
Each technique has its specific advantages and drawbacks. For instance, one of the 
biggest challenges of SLA is the cancerogenic risk of the photopolymerising material. 
Moreover, in no one of the included SLA studies was performed a test to evaluated the 
toxicity of the photopolymerising material and this non-evaluation represents a huge 
drawback and a reason for which this technique cannot be defined as the most suitable to 
print 3DP drug delivery systems. Moreover, as a future perspective, it is important to 
carry out this test, to evaluate the safety of the 3DP formulations before being adminis-
tered to the patients. 




The characterisation tests were performed and evaluated, to study the 3DP drug de-
livery systems, quantifying in how many articles were performed and which were the 
main factors affecting the results. During the development of the systematic review, six 
different characterisation tests (Table 1) were performed, to evaluate the quality and the 
mechanical properties of the 3DP oral solid formulations, following the BP specifications. 
In the following table, it is possible to observe that each test was performed with a differ-
ent percentage with the four 3DP techniques. 
Table 1. Schematic summaries of the six characterisation tests (drug content; dissolution profile; hardness; friability; dis-
integration; and uniformity of weight) performed with the four 3DP techniques (FDM; SLS, SLA; inkjet 3DP) and quanti-
fication in how many articles were evaluated. 
 Drug Content Dissolution Profile Hardness Friability Disintegration Uniformity of Weight 
FDM 68% 97% 51% 24% 18% 57% 
SLS 83% 100% 83% 17% 67% 67% 
SLA 100% 100% 37.5% 0% 0% 50% 
Inkjet 93% 93% 14% 21% 29% 43% 
The drug content was evaluated in most of all the techniques analysed, with a per-
centage above 90%, whereas only with FDM technique the value was a little lower com-
pared to the others (68%). This could represent a factor to improve in the future publica-
tions, where the FDM 3DP is used as printing technology, because as noticed early, once 
of the biggest challenges of this system, was the degradation of the drug(s), due to the 
high printing temperature, causing a reduction of the drug content in the 3DP formula-
tion. As shown in Figure 6, several polymers were used to manufacture 3DP formulations, 
and each of them has its specific degradation point and different applications. Further-
more, the choice of the printing temperature process depends on the degradation point of 
the drug and the melting temperature of the polymer. For instance, 4-ASA has a degrada-
tion temperature around 130–145 °C and to avoid the degradation, it is important to select 
both a printing temperature process below this range and a polymer, whose melting point 
is below the degradation temperature of the drug. 
The drug dissolution test was performed to evaluate the type of drug release profile, 
if immediate or sustained and the amount of drug released in a specific amount of time. 
It was carried out in almost all the articles included, for all the four techniques evaluated, 
with a percentage value equal to 100%. As represented in Figure 7, 76% of the 3DP formu-
lations had a sustained drug released, instead 24% an immediate one and as shown in 
Figure 5, the main FDM 3DP formulations were tablets (67%). Moreover, tablets are the 
preferred 3DP formulations, compared to the others, due to better physical and mechani-
cal properties, such as hardness and friability. Some authors noticed that some parameters 
affected the drug release profile, such as the tablet shape and the surface area to volume 
ratio (SA/V). Referred to this last parameter, it was observed an inverse correlation be-
tween the size and the drug release profile. Indeed, with a decrease in the size, there was 
an increase in the SA/V ratio and improvement of the drug release profile [20,41,42]. By 
contrast, other authors noticed that the drug release profile was affected by the amount of 
photocrosslinkable polymers, excipients, laser scanning speed, the intensity of the sinter-
ing process and porosity values [5,7,11,30]. Furthermore, a relevant consideration to carry 
out, it is that the factors which can affect the drug release profile, were different, based on 
the 3DP technique evaluated. 
The hardness test defined also as breaking force test was most performed in the SLS 
included articles, with a percentage equal to 83%. Considering FDM 3DP technique, this 
test was performed in only half of the cases (51%), whereas with inkjet 3DP in only a re-
duced number of publications [20] and some cases the hardness could not be evaluated, 
because the value was above the maximum limit measurable by the hardness tester (>800 




N), whereas in the works conducted by Khaled et al. the hardness had values within a 
range of 24.67 N to 24.78 N [40,44], instead of in the article carried out by Okwuosa et al. 
and Pietrzak et al. was 350 N and 490 N, respectively [46,47]. The main parameters which 
affected the hardness were the number of excipients added in the formulation and the 
laser scanning speed [1]. For instance, Fina et al. noticed an inverse correlation between 
the breaking force values and the laser scanning speed [25]. Moreover, considering how 
relevant is this parameter, it is important in the future works, to carry out this test, to 
evaluate if the 3DP drug delivery system is suitable or not for the intended use and if it 
meets the BP specifications. 
The friability test was performed in a limited number of publications (17–24%) in 
three of the four 3DP techniques, whereas with SLA was not performed. A possible expla-
nation could be due to the limited hardness values of the 3DP formulations, which were 
not able to undergo this type of test and this reduced friability evaluation represents an 
element that needs to be improved in the future works, being one of the tests required by 
the British Pharmacopeia (BP). 
Furthermore, the main parameter which affected the friability was the porosity of the 
binder particles, which had a direct correlation with the friability values, as reported by 
Infanger et al. [18]. Similarly, with all the FDM 3DP formulations the BP requirements 
were met, having friability values ≤1%. 
As for the friability, the disintegration test was not performed with SLA 3DP tech-
nique, whereas, with SLS was evaluated in 67% of the included articles. Moreover, this 
test also allowed to define if an immediate drug release profile formulation can be defined 
as ODT, based on the European Pharmacopeia and FDA definitions. For instance, in the 
work conducted by Jeong et al. and Khaled et al., the formulations had a disintegration 
time of less than 3 min and can be classified as ODTs [45,54]. Furthermore, the main pa-
rameters which affected the disintegration time were the binder viscosity [18], the infill 
percentage, water content and the printing pattern. Indeed, Palekar et al. observed a direct 
correlation between the infill percentage and the disintegration time. Moreover, higher is 
the infill percentage, less water can penetrate inside the formulation and faster will be the 
disintegration time [49]. 
The uniformity of weight was prevalently evaluated with SLS, 67% and as for the 
other characterisation tests, some parameters were affecting the weight uniformity, such 
as the laser scanning speed. For instance, Fina et al. noticed an inverse correlation within 
the uniformity of weight and the laser scanning speed. Indeed, an improvement of the 
laser scanning speed, led to an increase of the number of necks in each layer, to a subse-
quent reduction of the empty spaces and to the creation of more spaces, which can be 
occupied by the powder particles to be sintered. Consequently, all these elements allowed 
the production of denser and heavier tablets [30]. 
5. Conclusions and Future Perspectives 
3D printing is a revolutionary technique, which gives the possibility to manufacture 
patient-personalised formulations, offering a decrease of the costs and an increase of the 
adherence to the treatment. Moreover, one of its main application is the formulation of 
oral solid drug delivery systems and the four 3DP techniques, which have been more used 
for their manufacture are FDM (76%), inkjet 3DP (13%) SLA (7%) and SLS (4%). 
Considering Table 1, all the observations made related to the six characterisation tests 
and how frequently they have been evaluated, it is possible to conclude that SLS 3DP has 
been the technique where most of them have been evaluated with the highest percentages, 
except for the friability test, which was performed in only 17% (n = 1) of the included 
publications. 
However, it is not possible to define which is the most suitable technique to print oral 
solid formulations, because every 3DP technique has its advantages and disadvantages 
and the selection of the specific printing technique depends on the type of formulation 




which is desired to manufacture and on the physical-mechanical properties to achieve, 
such as hardness, friability or drug dissolution profile. Moreover, some improvements 
should be carried with all the four techniques evaluated, to perform all the six characteri-
sation tests and meet the acceptance criteria defined by the BP specifications for the man-
ufacture of tablets. 
The 3DP of medication is a new field in its infancy facing a number of challenges. 
One obstacle is the suitability of the 3DP techniques, as a number of the techniques could 
deter the stability of thermolabile drugs. Additionally, it is still challenging to prepare 
tablets that meet the legal requirements of the regulatory bodies and pharmacopeia. An-
other issue is the limited availability of ink materials that are compatible and suitable for 
preparation of oral medications. 
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3DP  Three-dimensional printing;  
3D  Three-dimensional;  
CAD  computer-aided design;  
PB  powder bed 3D printer;  
SLS  selective laser sintering; 
FDM  Fused Deposition Modelling;  
API  active pharmaceutical ingredient;  
FDA  Food and Drug Administration;  
SLA  stereolithography;  
PRISMA  
Preferred Reporting Items for Systematic 
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NIHR  National Institute for Health Research;  
AM  Additive Manufacturing;  
BP  British Pharmacopeia;  
DoP  drop-on-powder;  
DOD  drop-on-demand;  
SEM  Scanning electron microscopy;  
PVP  polyvinylpyrrolidone;  
SA/V  surface area to volume ratio;  
ODT  orally disintegrating tablet;  
PCL  polycaprolactone;  
PLGA  poly(lactic-co-glycolic acid);  
HME  Hot melt extrusion;  
HPMC  hydroxypropyl methylcellulose;  
PEO  polyethylene oxide;  
PEG  polyethylene glycol;  
TEC  triethyl citrate;  




TCP  tri-calcium phosphate;  
PVA  poly(vinyl alcohol);  
HCP  hydroxypropyl cellulose;  
EC  ethyl cellulose;  
HPMCAS  
hydroxypropyl methylcellulose acetate 
succinate;  
4-ASA  4-Aminosalicylic acid;  
5-ASA  5-Aminosalicylic acid;  
UV  ultraviolet;  





High Performance Liquid Chromatog-
raphy;  
DLP  Digital light processing;  
PEDGA  poly(ethylene glycol) diacrylate;  
USP  United States Pharmacopeia;  
CO2  carbon dioxide;  
IR  infrared;  
SD  standard deviation;  
EUD  Eudragit;  
FFF  Fused filament fabrication;  
STL  standard tessellation language;  
SLI  slice file;  
TGA  thermogravimetric analysis;  
ODPs  orodispersible printlets;  
TPO  
diphenyl(2,4,6-trimethylbenzoyl) phos-
phine oxide;  
PET  poly(ethylene terephthalate);  
FD-DDDs  fast-disintegrating drug delivery devices;  
MET  metformin hydrochloride;  
Para  Paracetamol;  
Asp  Aspirin.  
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